Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Randomized Placebo-controlled Dose-finding Phase II Study to Assess the Efficacy and Safety of Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

NCT05928390 is registered in ClinicalTrials.gov with RECORDATI GROUP as lead sponsor.

NCT NCT05928390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05928390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Randomized Placebo-controlled Dose-finding Phase II Study to Assess the Efficacy and Safety of Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Lead sponsor
RECORDATI GROUP
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 4, 2024
Completion date
October 29, 2026
Enrollment
93 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

post-bariatric hypoglycemia